Loading…
Jiangsu Meifan Biotechnology Co. Ltd., a Chinese manufacturer of over-the-counter drug products including antimicrobial hand wipes, failed to comply with Current Good Manufacturing Practice (CGMP) regulations, rendering their products adulterated. The company's primary violation was the failure to conduct adequate finished drug product testing prior to release, including the absence of appropriate assay tests for active ingredient content and impurities, as required by 21 CFR 211.165(a). This warning followed an FDA records request issued in August 2022 and was delivered in April 2024.